デフォルト表紙
市場調査レポート
商品コード
1412518

血液悪性腫瘍検査市場:製品タイプ、技術、疾患タイプ、エンドユーザー別-2024-2030年の世界予測

Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.86円
血液悪性腫瘍検査市場:製品タイプ、技術、疾患タイプ、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

血液悪性腫瘍検査市場規模は2023年に33億5,000万米ドルと推計され、2024年には36億米ドルに達し、CAGR 7.82%で2030年には56億9,000万米ドルに達すると予測されます。

血液悪性腫瘍検査の世界市場

主な市場の統計
基準年[2023] 33億5,000万米ドル
予測年[2024] 36億米ドル
予測年 [2030] 56億9,000万米ドル
CAGR(%) 7.82%
血液悪性腫瘍検査 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは血液悪性腫瘍検査市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、血液悪性腫瘍検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-血液悪性腫瘍検査市場の市場規模および予測は?

2-血液悪性腫瘍検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-血液悪性腫瘍検査市場における技術動向と規制の枠組みは?

4-血液悪性腫瘍検査市場における主要ベンダーの市場シェアは?

5-血液悪性腫瘍検査市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢化人口と血液悪性腫瘍の発生率の増加
      • 早期診断と治療への傾向
      • 免疫療法と分子標的薬の採用
    • 抑制要因
      • 高額な血液悪性腫瘍治療費
    • 機会
      • 個別化医療アプローチの重視
      • 世界的に臨床試験の数が増加
    • 課題
      • 血液悪性腫瘍に関連する副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 血液悪性腫瘍検査市場:製品別

  • 消耗品
  • サービス
  • 検査キット

第7章 血液悪性腫瘍検査市場:技術別

  • 蛍光In situハイブリダイゼーション
  • 免疫組織化学
  • 次世代シーケンス
  • ポリメラーゼ連鎖反応

第8章 血液悪性腫瘍検査市場:疾患タイプ別

  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • 骨髄異形成症候群
  • 骨髄増殖性腫瘍

第9章 血液悪性腫瘍検査市場:エンドユーザー別

  • 病院
  • 調査機関
  • 専門クリニック

第10章 南北アメリカの血液悪性腫瘍検査市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の血液悪性腫瘍検査市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの血液悪性腫瘍検査市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Adaptive Biotechnologies
    • Agilent Technologies, Inc.
    • Beckman Coulter, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • HORIBA, Ltd.
    • ICON PLC
    • Illumina, Inc.
    • Invitae Corporation
    • Invivoscribe, Inc.
    • Laboratory Corporation of America Holdings
    • Leica Biosystems Nussloch GmbH
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Nikon Instruments
    • Ortho Clinical Diagnostics
    • PerkinElmer Corporation
    • QIAGEN N.V.
    • Siemens AG
    • Sysmex Corporation
    • Sysmex Inostics Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET DYNAMICS
  • FIGURE 7. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 10. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 193. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. HEMATOLOGIC MALIGNANCIES TESTING MARKET LICENSE & PRICING
目次
Product Code: MRR-2E76C3E47FE0

[184 Pages Report] The Hematologic Malignancies Testing Market size was estimated at USD 3.35 billion in 2023 and expected to reach USD 3.60 billion in 2024, at a CAGR 7.82% to reach USD 5.69 billion by 2030.

Global Hematologic Malignancies Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.35 billion
Estimated Year [2024] USD 3.60 billion
Forecast Year [2030] USD 5.69 billion
CAGR (%) 7.82%
Hematologic Malignancies Testing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hematologic Malignancies Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hematologic Malignancies Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hematologic Malignancies Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., HORIBA, Ltd., ICON PLC, Illumina, Inc., Invitae Corporation, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., Natera, Inc., Nikon Instruments, Ortho Clinical Diagnostics, PerkinElmer Corporation, QIAGEN N.V., Siemens AG, Sysmex Corporation, and Sysmex Inostics Inc..

Market Segmentation & Coverage

This research report categorizes the Hematologic Malignancies Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Services
    • Testing Kits
  • Technology
    • Fluorescence In Situ Hybridization
    • Immunohistochemistry
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Disease Type
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
    • Myelodysplastic Syndrome
    • Myeloproliferative Neoplasms
  • End-Users
    • Hospitals
    • Research Institutions
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hematologic Malignancies Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hematologic Malignancies Testing Market?

3. What are the technology trends and regulatory frameworks in the Hematologic Malignancies Testing Market?

4. What is the market share of the leading vendors in the Hematologic Malignancies Testing Market?

5. Which modes and strategic moves are suitable for entering the Hematologic Malignancies Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hematologic Malignancies Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and incidences of hematologic malignancies
      • 5.1.1.2. Inclination toward early diagnosis and treatment
      • 5.1.1.3. Adoption of immunotherapies and targeted drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of hematologic malignancy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emphasis on personalized medicine approaches
      • 5.1.3.2. Increasing number of clinical trials globally
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with hematologic malignancies
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hematologic Malignancies Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Testing Kits

7. Hematologic Malignancies Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Fluorescence In Situ Hybridization
  • 7.3. Immunohistochemistry
  • 7.4. Next-Generation Sequencing
  • 7.5. Polymerase Chain Reaction

8. Hematologic Malignancies Testing Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Leukemia
  • 8.3. Lymphoma
  • 8.4. Multiple Myeloma
  • 8.5. Myelodysplastic Syndrome
  • 8.6. Myeloproliferative Neoplasms

9. Hematologic Malignancies Testing Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Hematologic Malignancies Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hematologic Malignancies Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hematologic Malignancies Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Adaptive Biotechnologies
    • 14.1.3. Agilent Technologies, Inc.
    • 14.1.4. Beckman Coulter, Inc.
    • 14.1.5. Becton, Dickinson and Company
    • 14.1.6. Bio-Rad Laboratories, Inc.
    • 14.1.7. F. Hoffmann-La Roche Ltd.
    • 14.1.8. HORIBA, Ltd.
    • 14.1.9. ICON PLC
    • 14.1.10. Illumina, Inc.
    • 14.1.11. Invitae Corporation
    • 14.1.12. Invivoscribe, Inc.
    • 14.1.13. Laboratory Corporation of America Holdings
    • 14.1.14. Leica Biosystems Nussloch GmbH
    • 14.1.15. Myriad Genetics, Inc.
    • 14.1.16. Natera, Inc.
    • 14.1.17. Nikon Instruments
    • 14.1.18. Ortho Clinical Diagnostics
    • 14.1.19. PerkinElmer Corporation
    • 14.1.20. QIAGEN N.V.
    • 14.1.21. Siemens AG
    • 14.1.22. Sysmex Corporation
    • 14.1.23. Sysmex Inostics Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing